The quarter was expected to be a cash-burn story, not a revenue event. Taysha remains pre-commercial, so the key comparison is operating loss and development progress. One published estimate put second-quarter EPS at roughly a $0.12 loss; reported EPS was a $0.13 loss, a narrow miss.
| Metric | Q2 2026 | Q2 2025 / comparison | Market read |
|---|---|---|---|
| Revenue | $0 | $1.986 million | Pre-commercial profile continues (Condensed Consolidated Statements of Operations) |
| R&D expense | $38.6 million | $20.1 million | Higher trial and manufacturing spending (Financial Highlights) |
| G&A expense | $12.1 million | $8.6 million | Higher launch-readiness and corporate costs (Financial Highlights) |
| Net loss | $46.6 million | $26.9 million | Larger loss as development activity accelerates (Financial Highlights) |
| Net loss per share | $0.13 loss | $0.09 loss | Slightly worse than published ~$0.12-loss consensus |
| Cash and equivalents | $455.4 million | $319.8 million at Dec. 31, 2025 | Funding strengthened by $230 million follow-on offering (Balance Sheet Data; Financial Highlights) |
The real operational milestone is complete enrollment and dosing in both pivotal-supporting studies. REVEAL reached 17 treated patients and ASPIRE reached four, while the company says all 33 treated patients across the program remain free of severe treatment-related serious adverse events and dose-limiting toxicities as of the August 2026 cutoff (Completed Dosing in the REVEAL Pivotal; Completed Dosing in the ASPIRE Trial; TSHA-102 Continues to be Generally Well-Tolerated). That reduces execution risk, but it does not yet establish pivotal efficacy because the six-month REVEAL interim analysis is still expected in the first half of 2027.
The efficacy language is encouraging but not a new decision-grade readout. Taysha cites broad, multi-domain functional gains that deepened through at least 12 months in earlier REVEAL Part A follow-up, but the filing provides no new response rate, control comparison, or quantitative pivotal-trial result (Presented Data Supporting TSHA-102 Clinical Program at IRSF). The market therefore gets better durability and safety framing, not the pivotal evidence needed to materially change approval odds.
The financing removes near-term funding risk but adds dilution. The $230 million offering lifts cash to $455.4 million and management says the runway extends into the second half of 2028, through potential BLA approval (Completed Public Follow-on Offering; Balance Sheet Data). However, shares outstanding rose to 325.3 million from 285.1 million at year-end, so the stronger balance sheet was purchased with meaningful equity dilution (Balance Sheet Data).
Net: operationally on schedule, financially slightly soft, and clinically still waiting for the decisive catalyst. Completion of dosing, manufacturing preparation, and cash runway are constructive, but much of that progress was anticipated and the filing does not bring forward the pivotal efficacy answer. The small EPS miss and dilution offset the execution positives, making the overall read mixed rather than clearly positive.
Read the original 8-K on SEC EDGAR ↗